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Abstract
Background: Measurement of blood hemoglobin (Hb) concentration is a routine procedure. Using a non-invasive point-of-
care device reduces pain and discomfort for the patient and allows time saving in patient care. The aims of the present
study were to assess the concordance of Hb levels obtained non-invasively with the Pronto-7 monitor (version 2.1.9, Masimo
Corporation, Irvine, USA) or with the NBM-200MP monitor (Orsense, Nes Ziona, Israel) and the values obtained from the
usual colorimetric method using blood samples and to determine the source of discordance.
Methods and Findings: We conducted two consecutive prospective open trials enrolling patients presenting in the
emergency department of a university hospital. The first was designed to assess Pronto-7
TM and the second NBM-200MP
TM.
In each study, the main outcome measure was the agreement between both methods. Independent factors associated with
the bias were determined using multiple linear regression. Three hundred patients were prospectively enrolled in each
study. For Pronto-7
TM, the absolute mean difference was 0.56 g.L
21 (95% confidence interval [CI] 0.41 to 0.69) with an upper
agreement limit at 2.94 g.L
21 (95% CI [2.70;3.19]), a lower agreement limit at -1.84 g.L
21 (95% CI [-2.08;-1.58]) and an intra-
class correlation coefficient at 0.80 (95% CI [0.74;0.84]). The corresponding values for the NBM-200MP
TM were 0.21
[0.02;0.39], 3.42 [3.10;3.74], -3.01 [-3.32;-2.69] and 0.69 [0.62;0.75]. Multivariate analysis showed that age and laboratory
values of hemoglobin were independently associated with the bias when using Pronto-7
TM, while perfusion index and
laboratory value of hemoglobin were independently associated with the bias when using NBM-200MP
TM.
Conclusion: Despite a relatively limited bias in both cases, the large limits of agreement found in both cases render the
clinical usefulness of such devices debatable. For both devices, the bias is independently and inversely associated with the
true value of hemoglobin.
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Introduction
After the introduction of pulse oximetry [1] which dramatically
improved patient care, particularly in acute conditions in the
emergency room (ER), the recent development of devices allowing
non-invasive and almost immediate measurement of hemoglobin
(SpHb) is promising.
Indeed, blood hemoglobin is routinely assessed mainly for two
purposes, to diagnose anemia, and then to pursue more invasive
testing,and to assess the need for bloodtransfusion.The cut-offvalues
leading to the diagnosisof anemia are widelyaccepted [2,3] whilethe
need for transfusion is decided after putting the hemoglobin value in
the perspective of the clinical context of the patient. In the emergency
department, as in other settings, laboratory measurement of
hemoglobin requires transport of samples thus delaying the process.
The potential improvement in patient care with a non-invasive
solution for measuring hemoglobin could be important as it gives the
result more rapidly, decreases exposure to potential biohazards, and
finally reduces pain and discomfort to the patient.
To date, four peer-reviewed publications [4,5,6,7] have assessed
non-invasive solutions for hemoglobin measurement. All of them
assessed the same technology using multi-wavelength pulse CO-
oximeters, namely the monitor Radical-7
TM (Masimo Corpora-
tion, Irvine, USA). The results of the four studies were discordant
and in three cases [4,5] a relatively large discrepancy was reported
between non-invasive measurements (SpHb) and classic measure-
ment (Hb-Lab). Since these reports, in order to improve the
accuracy of the non-invasive measurements, new monitors and
probes have been developed. Moreover, another monitor has
recently been released. This new device, namely the NBM-
200MP
TM (Orsense, Nes Ziona, Israel), uses differential light
absorption before and after blood flow obstruction in a finger to
determine hemoglobin level non-invasively. To date, no study
assessing this device has been published.
Accordingly, we report the results of two subsequent studies
using the same design, assessing two devices, the monitor Pronto-
7
TM (version 2.1.9, Masimo Corporation, Irvine, USA) and the
monitor NBM-200MP
TM. The two studies are hereafter referred
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the studies were i) to assess the concordance of hemoglobin levels
obtained non-invasively with the values obtained from the usual
colorimetric method in the hospital laboratory and using blood
samples and ii) to determine the source of errors in the
measurements.
Materials and Methods
Design and data analysis were strictly similar for the ‘‘Pronto-
Study’’ (ClinicalTrials.gov Identifier: NCT01321580) and the
‘‘Orsense-Study’’ (ClinicalTrials.gov Identifier: NCT01321593)
which were conducted consecutively (from December 15
th 2010
to February 15
th 2011 for the first and from February 15
th 2011 to
March 31
st for the second).
These studies were conducted in accordance with the STARD
guidelines (STAndards for the Reporting of Diagnostic accuracy
studies) [8].
Participants
These prospective open studies, performed in the emergency
department of a university hospital, were approved by the Ethics
Committee (CPP Ile-de-France VIII). Consecutive patients
examined by the same senior emergency nurse and requiring a
hemoglobin measurement were enrolled after they gave their
informed written consent. Only the laboratory results were used
for subsequent patient care.
Study protocol and measurements
Investigators recorded the hemoglobin level determined non-
invasively by the Monitor Pronto-7
TM (version 2.1.9) with the
Rainbow
H 4D DC sensor (revision B) (Masimo Corporation,
Irvine, USA) or by the monitor NBM-200MP
TM (Orsense, Nes
Ziona, Israel), with the probe placed on the patient’s finger, while
a nurse collected a venous blood sample in a EDTA (Ethylene-
DiamineTetraacetic Acid) tube, which was sent immediately to the
hematology laboratory for hemoglobin measurement by the
ADVIA
H 2120 (Siemens Medical Solutions Diagnostics, Zurich,
Switzerland). Three consecutive values of SpHb were collected;
the first two minutes after the probe had been placed on the
patient’s finger and two others after two minute intervals, all the
measurements were obtained over a 6 minute period. Only one
simultaneous blood sampling was performed for each patient. The
measure of hemoglobin level by the ADVIA
H 2120 method was
considered to be the gold-standard measure.
At the same time, body temperature, systolic and diastolic blood
pressure, peripheral oxygen saturation, perfusion index (displayed
on the Pronto-7
TM monitor or on the NBM-200MP
TM monitor)
and heart rate were collected. Of note, the Perfusion Index (PI) of
the Pronto-7 monitor provides a numeric indication of the pulse
strength at the measurement site. It is a calculated percentage
between the pulsatile signal and non-pulsatile signal of arterial
blood moving through the site. A similar index exists for the NBM-
200MP. However, concerning the Orsense device, unlike standard
sensors, the NBM sensor is located on the root of the finger, where
perfusion is better than in the fingertip and as the measurement is
based on occlusion spectroscopy technology it is thought to rely
less on the pulse signal.
During the procedure, the anxiety and the pain of the patients
were assessed using in both cases a visual analog scale (VAS). The
VAS was graphically represented as a horizontal line, 100
millimeter (mm) in length, with word descriptors at each end
(‘‘No pain’’ and ‘‘Very severe pain’’ for pain assessment and ‘‘I feel
totally relaxed’’ and ‘‘I feel highly anxious’’ for the anxiety
assessment’’). The patient marked on the line the point that they
felt represented their perception of their current state. The VAS
score was determined by measuring in mm from the left hand end
of the line to the point that the patient marked. The evaluation
was performed 2 min after the placement of the probe on the
patient’s finger and 2 min after the blood sampling.
Statistical analysis
Results are expressed as median and first and third quartiles
[Q1 to Q3] or counts and percentages. Comparison of values
obtained by the two methods was performed with a paired Student
t test. The individual values of SpHb and perfusion index (PI) were
defined as the mean of the three measurements. For the
concordance analysis, in both studies, we used the mean of the
three consecutive non-invasive measurements to define the value
of SpHb.
For agreement between the two hemoglobin determination
methods (invasive and non-invasive), a Bland–Altman analysis was
applied calculating bias as the mean difference between both
methods and limits of agreement as the range in which 95% of the
differences between the two methods are expected to lie [9]. The
intra-class correlation coefficient (ICC) between the two methods
was also estimated.
Multivariate linear regression was used to determine a set of
variables independently associated with bias. Bias was defined as
the absolute difference between the two measurements and was
expressed in g/dL. For continuous covariates, the linearity
assumption was checked using additive regression models with
splines. Model goodness-of-fit was assessed by examination of
residuals (quantile to quantile plots and residuals versus fitted
plots).
The percentage of variation over the three non-invasive
measurements was determined. First, the variation was calculated
for each of the three measurements, then the highest value was
used to define the individual coefficient of variation of the non-
invasive measurement.
The within-subject coefficient of variation of each noninvasive
and invasive technique was calculated by analyzing 15 different
samples in duplicate. The coefficient of variation is defined as the
ratio of the standard deviation of the absolute difference between
the duplicates divided by the mean of the average value of the
duplicate [10].
According to the methods developed for reliability study [11],
the calculated sample size was 270. Based on previous work on
hemoglobin assessment [12], the hypothesis to obtain this sample
size was an expected ICC at 0.88 with a width of the confidence
interval at 0.1. Given a rate of inconclusive measurements or lost
to follow-up of 10%, the number of patients to include was 300 in
each study.
Comparisons of pain and anxiety VAS scores were also
performed using non-linear mixed effect models, in order to take
into account the intra-subject correlation.
A two-sided p-value of 0.05 was considered significant. All
analyses were performed using R 2.10.1 statistical software (The R
Foundation for Statistical Computing, Vienna, Austria).
Results
Patients’ characteristics
Three hundred patients were prospectively included in each
study. The flow chart of the studies is shown in Figure 1. Patient
characteristics are described in Table 1. Principal causes for
admission to the emergency ward were abdominal pain (21%),
thoracic pain (13%), dyspnea (12%) and sepsis (8%). Seven per
Non-Invasive Measurement of Hemoglobin
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history of, bleeding. None of the patients’ characteristics were
different between the two studies. Non-invasive hemoglobin values
could not be obtained in 5 patients when using the Pronto-7
hemoglobin-meter and in 2 patients when using the NBM-
200MP
TM. Laboratory measure was not obtained in 23 patients in
the Pronto-Study and in 1 patient in the Orsense-Study, because
of discharge from the ER prior to the blood sample. As depicted in
figure 2, the distribution of hemoglobin levels in the two studied
populations was similar even for the extreme values.
Figure 1. Flow chart of the studies (Pronto-7
TM on panel A and Orsense on panel B).
doi:10.1371/journal.pone.0030065.g001









Age (years) 57 (42 to 74) 57 (43 to 75) 58 (41 to 74) 0.68
Male gender 297 (52.2) 140 (51.5) 157 (52.9) 0.74
Height (cm) 170 (162 to 175) 170 (162 to 175) 170 (162 to 175) 0.8
Weight (kg) 70 (60 to 80) 70 (59 to 81.8) 68.5 (60 to 80) 0.15
Reasons for ER admission 0.13
Abdominal pain 122 (21) 48 (18) 74 (25)
Fatigue 36 (6) 17 (6) 19 (6)
Bleeding 39 (7) 20 (7) 19 (6)
Chest pain 74 (13) 36 (13) 38 (13)
Dyspnea 70 (12) 38 (14) 32 (11)
Faintness 38 (7) 17 (6) 21 (7)
Other neurological disorders 55 (10) 21 (8) 34 (11)
Other 73 (13) 45 (17) 28 (9)
Infection 40 (7) 22 (8) 18 (6)
Trauma 20 (4) 8 (3) 12 (4)
Anemia 2 (0) 0 (0) 2 (1)
Hemodynamics at admission
SBP (mmHg) 133 (114 to 150) 134 (116 to 151) 132 (113.8 to 148) 0.32
DBP (mmHg) 81 (72 to 90) 81 (72 to 90) 81 (72 to 90) 0.51
HR (bpm) 86 (75 to 99) 87 (76.5 to 101) 85 (73 to 98) 0.089
SpO2 (%) 98 (96 to 99) 98 (96 to 99) 98 (96 to 99) 0.19
Hemoglobin measured in the laloratory (g/dL) 13.2 (11.9 to 14.3) 13.2 (11.9 to 14.3) 13.2 (12.1 to 14.2) 0.73
(See text for details).
(SBP: systolic blood pressure. DBP: diastolic blood pressure. HR: heart rate. SpO2: pulse-oximeter saturation).
doi:10.1371/journal.pone.0030065.t001
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measurements
The Bland-Altman graphical representation of the concordance
is reported in Figure 3. Table 2 depicts the concordance
parameters of the two studies. For Pronto-7
TM, the absolute mean
difference was 0.56 g.L
21 (95% confidence interval [CI] 0.41 to
0.69) with an upper agreement limit at 2.94 g.L
21 (95% CI 2.70 to
3.19), a lower agreement limit at -1.84 g.L
21 (95% CI -2.08 to
-1.58) and an intra-class correlation coefficient at 0.80 (95% CI
0.74 to 0.84). The corresponding values for the NBM-200MP
TM
monitor were 0.21 [0.02; 0.39], 3.42 [3.10; 3.74], -3.01 [-3.32;
-2.69] and 0.69 [0.62; 0.75].
Independent predictors of bias
In univariate analysis, age, diastolic blood pressure and the
hemoglobin value when assessed in the laboratory were signifi-
cantly associated with the bias associated with Pronto-7
TM.
Similarly, in univariate analysis, gender, heart rate, body
temperature, perfusion index and the hemoglobin value when
assessed in the laboratory were significantly associated with the
bias associated with Orsense
TM (Table 3). Multivariate analyses
led to identification of two independent factors associated with the
bias for Pronto-7
TM: age and true value of hemoglobin (mean
difference [95% CI]: -0.14 [-0.20; -0.08 ] for 10 years and -0.32
[ -0.38; -0.26 ] for 1 g/dL, respectively). Similarly, perfusion index
and true value of hemoglobin were both independently associated
with the bias of the measurement of Orsense
TM (mean difference
[95% CI]: 0.339 [0.339-0.340] for 1 unit and -0.998 [-0.997;-
1.000] for 1 g/dL, respectively).
Figure 4 depicts the inverse linear relationship between the
bias and the true value of hemoglobin found in both studies
(Pearson’s correlation coefficient at -0.51, 95% CI [-0.59; -0.41],
p,0.0001 for the Pronto-Study and at -0.37, 95% CI [-0.46;
-0.26], p,0.0001for the Orsense-Study).
Similarly, Figure 5 illustrates the relationship between bias and
perfusion index. Although there is no significant relationship
between PI and bias for the Pronto-Study, there is a linear
relationship between bias and PI for the Orsense-Study.
Concerning the PI, the Pearson’s correlation coefficient with the
Figure 3. Bland and Altman graphical representation of the concordance between the laboratory value of hemoglobin and SpHb.
Results for the Pronto-Study are displayed on the panel A and for the Orsense-Study on the panel B. The plain horizontal blue line represents the
mean bias and the dashed horizontal blue lines represent the upper and the lower limits of agreement.
doi:10.1371/journal.pone.0030065.g003
Figure 2. Distribution of hemoglobin value in the two populations studied. As depicted in the figure, the overlap of hemoglobin values
between the two populations studied is almost complete all along the range of hemoglobin values.
doi:10.1371/journal.pone.0030065.g002
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Repeatability of the measurements
The within-subject coefficients of variation were 1.3% for the
ADVIA 2120, 3.5% for the Pronto 7
TM and 5.9% for the NBM-
200MP
TM. Figure 6 depicts in three dimensions the difference
between the three non-invasive determinations of the hemoglobin
value in each patient for the two devices. For Pronto-7
TM, the
mean percentage of variation was 2.7%63% and variation was
higher than 10% in 11 (4%) patients and lower than 2.5% in 194
(71%) patients. The corresponding values for NBM-200MP
TM
were 5.1%64.1% for the mean percentage of variation. Variation
was higher than 10% in 18 (6%) patients and lower than 2.5% in
139 (46%) patients.
Anxiety and pain assessment
The pain and anxiety VAS scores were significantly lower
w i t ht h en o n - i n v a s i v em e a s u rement in both studies. The
differences for pain on the VAS scale were 1.62 [1.33; 1.91]
(p,0.0001) and 1.62 [1.33; 1.91] (p,0.0001) in the Pronto-
Study and the Orsense-Study respectively. Similarly, the
differences for anxiety were 1.00 [0.70; 1.25] (p,0.0001) and
0.8 [0.6; 1.1] (p,0.0001).
Discussion
Compared to previous reports [4], our study showed an
improvement in the accuracy of the devices with a bias close to
or lower than 0.5 g/dL in both cases. However, the limits of
agreement are still large, higher than 2 g/dL in both cases also.
Compared to previous reports [4,5,6,7], which all studied a
previous version of the same device, namely the Radical 7
TM
(Masimo Corporation), along with the reduction in bias, we
showed several other improvements associated with this new
version of the device. Concerning the monitor Pronto-7
TM, the
repeatability of the measure is lower than previously reported but
still in accordance with the required standard, fixed at 1.4% [10].
Although two factors, age and laboratory value of hemoglobin,
independently affected the bias, the SpO2 is no longer associated
with the bias; this constitutes a improvement compared to previous
findings[4],[13]. Moreover, the rate of impossible measurement
with the studied version of the device (,2.5%) is lower than
previously reported (8%) [4]. Another study showed an apparent
relationship between the variability of the SpHb and the perfusion
index when using the Radical 7
TM monitor [7], this source of
variability was not present in the new version, Pronto-7
TM. The
bias and the limits of agreement in the present study are higher
than in a previously published one using the previous version of
the device [6]. However, the latter involved only 35 volunteers and
studied repeated measurements, whereas we chose to use one
measurement per patient on a large sample. Our results on
Pronto-7
TM are in accordance with the results of the study
conducted by Hahn et al. [5]. This study, not focused on
concordance but on volume kinetic analysis of infusion fluids,
reported an important variability in the non-invasive hemoglobin
measurement, which differed more than 7.5% from the invasive
hemoglobin in half of the paired data points. The authors
concluded that non-invasive measurement of the hemoglobin
concentration (using also the Radical-7
TM device) during volume
loading could not provide useful kinetic data for individuals [5].
Moreover, the recent study conducted by Miller et al. [7] showed
limits of agreement higher than 30 g/L, similar to ours. Of note,
the sample size of all previously above mentioned published works
was lower than in the present study and three of those used
repeated measures [5,6,7].




Bias [95% CI] (g/dL) 0.56[0.41; 0.69] 0.21 [0.02; 0.39]
Upper limit of agreement
[95% CI] (g/dL)
2.94[2.70; 3.19] 3.42 [3.10; 3.74]
Lower limit of agreement
[95% CI] (g/dL)
-1.84[-2.08; -1.58] -3.01 [-3.32; -2.69]
ICC coefficient
[95% CI] (g/dL)
0.80 [0.74; 0.84] 0.69 [0.62; 0.75]
Coefficient of variation (CV) 3.5% 5.9%
(ICC: intra-class correlation. CI: confidence interval).
doi:10.1371/journal.pone.0030065.t002





[95% CI] p value
Effect on bias
[95% CI] p value
Age (for 10 years) -0.08 [ -0.15 ; -0.0 ] 0.0288 0 [ -0.01 ; 0 ] 0.2827
Gender 0 [ -0.29 ; 0.28 ] 0.9808 0.46 [ 0.1 ; 0.83 ] 0.013
SBP (mmHg) 0 [ -0.01 ; 0 ] 0.0969 0 [ -0.01 ; 0 ] 0.458
DBP (mmHg) -0.01 [ -0.02 ; 0 ] 0.0031 0 [ -0.01 ; 0.01 ] 0.7281
HR (bpm) 0.01 [ 0 ; 0.01 ] 0.071 0.01 [ 0 ; 0.02 ] 0.0359
SpO2 (%) 0.03 [ -0.02 ; 0.08 ] 0.3176 0 [ -0.03 ; 0.02 ] 0.7687
Body temperature (uC) 0.07 [ -0.1 ; 0.25 ] 0.4106 0.3 [ 0.06 ; 0.54 ] 0.0167
Perfusion index -0.01 [ -0.05 ; 0.02 ] 0.3598 0.11 [ 0.08 ; 0.14 ] , 0.0001
Hb-Lab -0.3 [ -0.36 ; -0.24 ] , 0.0001 -0.29 [ -0.38 ; -0.21 ] , 0.0001
(CI: confidence interval. SBP: systolic blood pressure. DBP: diastolic blood pressure. HR: heart rate. SpO2: pulse-oximeter saturation. Hb-Lab: hemoglobin value obtained
invasively. PI: perfusion index. VAS: visual analogical scale).
doi:10.1371/journal.pone.0030065.t003
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TM shows a small
bias but limits of agreement higher than 3 g/dl and an ICC
coefficient lower than 0.8. Moreover, the measure seems to be
unstable, with a mean coefficient of variation at 5.9% and an
absolute difference between two consecutive measurements lower
than 2.5% in less than 50% of the cases. For this monitor also, the
bias is independently affected by the true level of hemoglobin and
the index of perfusion is also independently associated.
The two studied monitors showed slight differences in
performance. These differences could be explained by the fact
that the technology used is not the same. Indeed, Pronto-7
TM and
NBM-200MP
TM are both non-invasive solution for on-line,
continuous and spot hemoglobin measurements combined with
oximetry measurements, but the first uses more than seven
wavelengths of light to acquire blood constituent data based on
light absorption through a finger probe. The second involves a
ring-shaped sensor fitted on the patient’s finger that temporarily
gently squeezes the finger to over-systolic pressure, similar to blood
pressure measurements. Moreover, the signal processing algo-
rithms and filters used are not the same in both cases. In contrast
with these differences in performance, both devices were
associated with a reduction in pain and anxiety scales with the
non-invasive measure, regardless of the monitor used. Even if this
result is to be expected, it is interesting for the improvement in
patient care associated with the use of such point-of-care methods.
A noninvasive and accurate estimation of hemoglobin could
have many roles in patient care, for example as an early warning
system for bleeding, as a way of monitoring high risk patients for
bleeding (for instance patients on antiplatelet therapy, cirrhotic
patients, arterio-venous malformations, recurrence of peptic ulcer
Figure 4. Association between true values of hemoglobin and bias. Results for the Pronto-Study are displayed on the panel A and for the
Orsense-Study on the panel B. The red line represents the linear regression relationship between the true value of hemoglobin and the bias. There is
an inverse correlation between hemoglobin and bias in both studies (Spearman correlation coefficients at - 0.51, p ,0.0001 and -0.37, p,0.0001 for
the Pronto-Study and the Orsense-study, respectively).
doi:10.1371/journal.pone.0030065.g004
Figure 5. Association between perfusion index and bias. Results for the Pronto-Study are displayed on the panel A and for the Orsense-Study
on the panel B. The red line represents the linear regression relationship between the perfusion index and the bias. Perfusion index is linearly
correlated with the bias in Orsense-Study but not in the Pronto-Study (Spearman correlation coefficients at - 0.06, p=0.36 and 0.42, p,0.0001 for the
Pronto-Study and Orsense-study, respectively).
doi:10.1371/journal.pone.0030065.g005
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abruption), and as a screening tool for people who have difficult
venous access. It also has many theoretical advantages, such as its
ability to perform repeated sampling without causing iatrogenic
blood loss linked to anemia, particularly in the intensive care unit
and also its ability to monitor hemoglobin concentrations in a
pediatric population.
Hemoglobin can also be measured through the use of other
transportable, portable, and handheld instruments at or near the
site of patient care (point-of-care testing). HemoCue
H (HemoCue
Ltd, Sheffield) provides a quick and acceptable estimation of
hemoglobin compared to laboratory measurements but requires
taking a blood sample[14,15]. Interestingly, Miller et al.
demonstrated that HemocueH presented a better performance
compared to non-invasive measurement using the Radical-7
TM
monitor from Masimo[7]. Further studies are needed to evaluate




Even if the two populations involved in the two studies reported
in the present article seem comparable, the two devices were not
compared in a single trial. Therefore, no direct comparison of
their performance is possible. A comparative trial was not
conducted for technical reasons, as the two devices were not
available at the same time in our center. However, because of the
identical design, the large sample size and the comparability of the
two samples, results can be compared. The study was performed in
a single center; this could limit generalization of the results.
However, the large sample size led to include patients with various
medical conditions. Even if the rate of anemic patients was around
30% in both studies, few patients presented extreme values of
hemoglobin and the results of the studies may not be generalizable
to them. Thus, further studies are needed to address this issue.
Moreover, it would be interesting to test theses devices in the
setting of significant fluid shifts, blood loss or active bleeding, as
they are common situations occurring in the operating room, or
after major trauma. The performance of the studied devices needs
to be assessed in these situations.
Finally, although we studied the latest version of the device
produced by Masimo, we assessed the first one produced by
Orsense and another version, specifically designed for spot-check
measurement, namely NBM-200
TM, exists but was not assessed in
the present study. This could explain the slight difference between
the two devices and so further investigations are needed to
evaluate this alternative version.
Conclusion
In short, two devices dedicated to non-invasive measurement of
hemoglobin were assessed in the present study. Bias was found to
be small but independently and inversely associated with the true
value of hemoglobin. Of more importance is that limits of
agreement are large in both cases making the clinical usefulness of
such devices debatable.
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